Literature DB >> 20057989

[Hormonal contraception for men: still a current issue].

M Zitzmann1.   

Abstract

The current status of hormonal contraception in men involves the principle of suppression of gonadotropins, LH, and FSH. This must be achieved as completely as possible to facilitate cessation of spermatogenesis and, thus, reach azoospermia. Simultaneously testosterone has to be replaced. Exogenous testosterone administration achieves the goal of gonadotropin suppression, but needs in addition the supplementation of a gestagen to fully suppress secretion of LH and FSH. Suppression of gonadotropins by steroids requires constant serum concentrations of sex steroids; hence, attempts using daily oral or transdermal preparations were, so far, unsuccessful. Thus, the immediate prospect for male contraception is not a"pill" itself but a regimen of combined injectable steroids, which are in advanced clinical testing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20057989     DOI: 10.1007/s00120-009-2193-z

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

Review 1.  Male contraception.

Authors:  R A Anderson; D T Baird
Journal:  Endocr Rev       Date:  2002-12       Impact factor: 19.871

2.  A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception.

Authors:  Cathy J Hay; Brian M Brady; Michael Zitzmann; Kaan Osmanagaoglu; Pasi Pollanen; Dan Apter; Frederick C W Wu; Richard A Anderson; Eberhard Nieschlag; Paul Devroey; Ilpo Huhtaniemi; Wendy M Kersemaekers
Journal:  J Clin Endocrinol Metab       Date:  2005-01-25       Impact factor: 5.958

3.  A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive.

Authors:  B M Brady; J K Amory; A Perheentupa; M Zitzmann; C J Hay; D Apter; R A Anderson; W J Bremner; P Pollanen; E Nieschlag; F C W Wu; W M Kersemaekers
Journal:  Hum Reprod       Date:  2005-09-19       Impact factor: 6.918

4.  Endogenous progesterone and the exogenous progestin norethisterone enanthate are associated with a proinflammatory profile in healthy men.

Authors:  Michael Zitzmann; Michael Erren; Axel Kamischke; Manuela Simoni; Eberhard Nieschlag
Journal:  J Clin Endocrinol Metab       Date:  2005-10-04       Impact factor: 5.958

5.  Would women trust their partners to use a male pill?

Authors:  A F Glasier; R Anakwe; D Everington; C W Martin; Z van der Spuy; L Cheng; P C Ho; R A Anderson
Journal:  Hum Reprod       Date:  2000-03       Impact factor: 6.918

6.  Attitudes toward male fertility control: results of a multinational survey on four continents.

Authors:  Klaas Heinemann; Farid Saad; Martin Wiesemes; Steven White; Lothar Heinemann
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

7.  Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis.

Authors:  Peter Y Liu; Ronald S Swerdloff; Peter D Christenson; David J Handelsman; Christina Wang
Journal:  Lancet       Date:  2006-04-29       Impact factor: 79.321

8.  Multicenter contraceptive efficacy trial of injectable testosterone undecanoate in Chinese men.

Authors:  Yiqun Gu; Xiaowei Liang; Weixiong Wu; Minli Liu; Shuxiu Song; Lifa Cheng; Liwei Bo; Chengliang Xiong; Xinghai Wang; Xiaozhang Liu; Lin Peng; Kangshou Yao
Journal:  J Clin Endocrinol Metab       Date:  2009-03-17       Impact factor: 5.958

Review 9.  Use of progestins in male contraception.

Authors:  Eberhard Nieschlag; Michael Zitzmann; Axel Kamischke
Journal:  Steroids       Date:  2003-11       Impact factor: 2.668

10.  Male hormonal contraception: a double-blind, placebo-controlled study.

Authors:  Ellen Mommers; Wendy M Kersemaekers; Jörg Elliesen; Marc Kepers; Dan Apter; Hermann M Behre; Jennifer Beynon; Pierre M Bouloux; Antonietta Costantino; Hans-Peter Gerbershagen; Lars Grønlund; Doris Heger-Mahn; Ilpo Huhtaniemi; Evert L Koldewijn; Corinna Lange; Svend Lindenberg; M Cristina Meriggiola; Eric Meuleman; Peter F A Mulders; Eberhard Nieschlag; Antti Perheentupa; Andrew Solomon; Leena Väisälä; Frederick C Wu; Michael Zitzmann
Journal:  J Clin Endocrinol Metab       Date:  2008-04-15       Impact factor: 5.958

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.